简介：Objective:Survivalandtreatmentofpatientswithmicroinvasivebreastcancer(MIBC)remaincontroversial.Inthispaper,weevaluatedwhetheradjuvantchemotherapyisnecessaryforpatientswithMIBCtoidentifyriskfactorsinfluencingitsprognosisanddecidetheindicationforadjuvantchemotherapy.Methods:Inthisretrospectivestudy,108patientswithMIBCwererecruitedaccordingtoseventheditionofthestagingmanualoftheAmericanJointCommitteeonCancer(AJCC).Thesubjectsweredividedintochemotherapyandnon-chemotherapygroups.Wecomparedthe5-yeardisease-freesurvival(DFS)andoverallsurvival(OS)ratesbetweengroups.Furthermore,weanalyzedthefactorsrelatedtoprognosisforpatientswithMIBCusingunivariateandmultivariateanalyses.Wealsoevaluatedtheimpactofadjuvantchemotherapyontheprognosticfactorsbysubgroupanalysisaftermedianfollow-uptimeof33months(13-104months).Results:The5-yearDFSandOSratesforthechemotherapygroupwere93.7%and97.5%,whereasthoseforthenonchemotherapygroupwere89.7%and100%.Resultsindicatethat5-yearDFSwassuperior,butOSwasinferior,intheformergroupcomparedwiththelattergroup.However,nostatisticalsignificancewasobservedinthe5-yearDFS(P=0.223)orOS(P=0.530)rateofthetwogroups.Mostrelevantpoor-prognosticfactorswereKi-67overexpressionandnegativehormonalreceptors.Cumulativesurvivalwas98.2%vs.86.5%betweenlowKi-67(≤20%)andhighKi-67(>20%).ThehazardratioofpatientswithhighKi-67was16.585[95%confidenceinterval(CI),1.969-139.724;P=0.010].Meanwhile,ER(-)/PR(-)patientswithMIBChadcumulativesurvivalof79.3%comparedwith97.5%forER(+)orPR(+)patientswithMIBC.ThehazardratioforER(-)/PR(-)patientswithMIBCwas19.149(95%CI,3.702-99.057;P<0.001).SubgroupanalysisshowedthatchemotherapycouldimprovetheoutcomesofER(-)/PR(-)patients(P=0.014),butnotthosewhooverexpressKi-67(P=0.105).Conclusions:PatientswithMIBCwhooverexpressKi-67and

简介：CHAARTED是在荷尔蒙敏感的前列腺癌症独自除了雄激素剥夺治疗(ADT)对ADT与docetaxel的使用看早化疗的带ECOG的阶段III试用。在与ADT收到了化疗的那些在全面幸存显示出显著改进的试用的积极结果革命化了变形阉割敏感的前列腺癌症的治疗。除了全面幸存，第二等的端点象阉割抵抗的时间那样，PSA反应为收到了早化疗的病人也是重要的。

简介：Objective:Theaimofthisprospective,single-armphaseIItrialwastoconfirmthesafetyandefficacyofneoadjuvantchemotherapy(NAC)usingoxaliplatinpluscapecitabine(CapOX)forpatientswithoperablelocallyadvancedcoloncancer(CC).Methods:Patientswithcomputedtomography-definedT4orlymphnode-positiveCCswereenrolled.Afterradiologicalstaging,patientsweretreatedwithatleast2cyclesofNACconsistingof130mg/m2oxaliplatinond1,plus1,000mg/m2capecitabinetwicedailyfor14devery3weeks,followedbysurgery,andthenwiththerestcyclesofadjuvantchemotherapy.Radiologicalresponsewasevaluatedafter2cyclesofNAC.Tumorresponse,treatmenttoxicity,andsurgicalcomplicationswererecorded.Thepathologicalresponsetotherapywasevaluatedaccordingtothetumorregressiongrade(TRG)score.Theprimaryendpointwaspathologictumorresponse.ThistrialisregisteredinClinicalTrials.gov(No:NCT02415829).Results:Forty-sevenpatientswereenrolledinthestudy.Forty-twopatientscompletedtheplannedtreatments.Thetotalradiologicalresponseratewas68%(32/47),includingcompleteandpartialresponseratesof2%(1/47)and66%(31/47),respectively.Stablediseasewasobservedin32%(15/47)andprogressivediseasewasobservedinnone.Completepathologicresponse,majorregression,andatleastmoderateregressionwereachievedin1(2%),2(4%),and29(62%)patients,respectively.Fourpatientsdevelopedgrade3treatmenttoxicities.Onepatientwithwoundinfectionoccurredafteroperation(1/47,2%).Therewasnotreatment-relateddeath.Conclusions:OurresultssuggestthatNACwithCapOXisaneffectiveandsafetreatmentoptionforpatientswithlocallyadvancedCCs.

简介：在这份报纸，我们独自考察了雄激素剥夺治疗(ADT)的长期的幸存结果，安全，和quality-of-life对为局部地先进、变形的前列腺癌症(PCa)与放射治疗(RT)或化疗结合了。文学搜索用OvidSP被执行。满足了下列标准的使随机化的控制试用(RCT)被包括：包括局部地先进或变形的PCa，比较方法和疾病的报导量的数据控制的与任何治疗独自一个对联合的ADT或幸存结果。最后，八RCT满足了包括标准。在这些之中，三比较了ADT对ADT正RT(n=2344)并且一个人比较了ADT对ADT正docetaxel-estramustine(n=413)在局部地先进的PCa；二比较了ADT对ADT正docetaxel(n=1175)并且加estramustine的二比较ADT对ADT(n=114)在变形PCa。为局部地先进的PCa，到长期的ADT的RT的增加能与充分可接受的不利效果改进幸存和肿瘤控制的结果。特殊，分享的机会比率(或)外套，幸存(OS)是1.43(95%信心间隔1.20-1.71)什么时候独自加RT把ADT与ADT作比较(P<0.0001)。为变形神经质地敏感的PCa，加ADT的docetaxel的并发的使用有效、安全(分享或OS：1.29[1.01-1.65]：P=0.04)。总共，加docetaxel的长期的ADT正RT和长期的ADT应该分别地在局部地先进、变形的神经质地敏感的PCa被看作合适的处理选择。为纸的主要限制是仅仅八RCT是可得到的。